Eli Lilly is about to release its financial report, what is the market focusing on?
Ai Focus
Eli Lilly is expected to announce its third-quarter revenue and profits on Thursday. Analysts predict earnings per share of $6.26 and revenue of $22.61 billion. Investors will also be watching the sales performance of its weight-loss drug Foundayo, as well as the company's mergers and acquisitions in an environment of low net selling prices.
Eli Lilly is expected to announce its third-quarter revenue and profits on Thursday, and the performance is likely to be driven by its best-selling weight loss drug Zepbound as well as its diabetes medication Mounjaro.
According to the survey of analysts by LSEG, the current expectations on Wall Street are as follows:
- Earnings per share: Estimated at $6.26
- Revenues: Estimated at $22.61 billion
However, investors will also be closely watching the listing progress of the company's weight loss drug Foundayo. This drug entered the market in April. Estimates from StreetAccount suggest that analysts predict sales for this drug to be around $229 million.
Lilly's substantial profits in the fields of diabetes and weight loss, as well as its leading position compared to its main competitor Novo Nordisk, seem to show no signs of slowing down, despite the company facing lower net selling prices in the US market. This pharmaceutical giant is transforming these historic profits into a series of large-scale transactions: it reached an agreement to acquire a psychedelic drug manufacturer in July and announced plans to acquire three vaccine manufacturers in May.
Follow WalletJYS official accounts to stay updated
Views 21
WalletJYS reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”，and we will handle it promptly。
No comments yet. Be the first!
6 
Recurrent Energy completes the sale of two French MW /400 MWh BESS projects to BW ESSCanadian Solar's subsidiary Recurrent Energy announces that it has sold two independent battery energy storage system (BESS) projects in France to BW ESS. The two projects have a combined installed capacity of 200 MW / 800 MWh. Recurrent Energy stated that it will continue to advance the remaining development stages, while BW ESS plans to hold and operate these assets in the long term.
PR Newswire
·2026-10-29 19:13:175 
7 
First Mid Bancshares Announces Acquisition of Evergreen BancsharesFirst Mid Bancshares and Evergreen Bancshares announce the signing of a final agreement. First Mid will acquire all issued shares of Evergreen in the form of stocks plus cash. The total transaction value is approximately 70.7 million US dollars, with completion expected in the first quarter of 2027. The deal is still subject to regulatory approval and the approval of the shareholders of Evergreen.
GlobeNewswire
·2026-10-29 19:13:088 
Goldman Sachs and JPMorgan Chase lower target prices for Alphabet after financial reportsAfter the release of Alphabet's third-quarter financial report, both JPMorgan Chase and Goldman Sachs lowered their target prices. Search business revenue fell short of expectations, foreign exchange headwinds continued, and capital expenditures remained high with an expected further increase in 2027, putting pressure on free cash flow prospects; however, Google Cloud's revenue and profit margins performed strongly, becoming the main highlights of the quarter.
Wallstreetcn
·2026-10-29 19:02:5315 View More
